top of page

About Us
Journal
Platform
Pipeline
Engage
Contact

Canurta Website Images.jpg

Canurta Journal

A collection of news, scientific papers and impact across industry, academia and events.

All Posts
Research
Events
Awards
News
Blog
Newsletter

August Letter from The CEO

August Letter from The CEO

August Letter from The CEO

Aug 11

New Study Shows Hemp Flavonoids May Protect Cartilage

New Study Shows Hemp Flavonoids May Protect Cartilage

New Study Shows Hemp Flavonoids May Protect Cartilage

Aug 5

Polykye Formulations™ Launch, SOVEREIGN 2026 Concludes, and New Research Published

Polykye Formulations™ Launch, SOVEREIGN 2026 Concludes, and New Research Published

Polykye Formulations™ Launch, SOVEREIGN 2026 Concludes, and New Research Published

Jun 2

Canurta Naturals Launches Hemp Flavonoid Complex™, SOVEREIGN 2026 Sells Out, and New Scientific Paper Published

Canurta Naturals Launches Hemp Flavonoid Complex™, SOVEREIGN 2026 Sells Out, and New Scientific Paper Published

Canurta Naturals Launches Hemp Flavonoid Complex™, SOVEREIGN 2026 Sells Out, and New Scientific Paper Published

May 6

Registration Opens for SOVEREIGN 2026, New Partnership Opportunities with Canurta Naturals, and Continued Progress Toward PharmaDrug 2nd Tranche

Registration Opens for SOVEREIGN 2026, New Partnership Opportunities with Canurta Naturals, and Continued Progress Toward PharmaDrug 2nd Tranche

Registration Opens for SOVEREIGN 2026, New Partnership Opportunities with Canurta Naturals, and Continued Progress Toward PharmaDrug 2nd Tranche

Apr 8

Preprint Study Examines Transcriptomic Effects of CNR-401 and Cannflavin A in an ALS Model

Preprint Study Examines Transcriptomic Effects of CNR-401 and Cannflavin A in an ALS Model

Preprint Study Examines Transcriptomic Effects of CNR-401 and Cannflavin A in an ALS Model

Mar 13

Canurta Expands Global Reach with extractX Partnership, Strategic MOU, and Continued Biosynthesis Validation

Canurta Expands Global Reach with extractX Partnership, Strategic MOU, and Continued Biosynthesis Validation

Canurta Expands Global Reach with extractX Partnership, Strategic MOU, and Continued Biosynthesis Validation

Mar 3

Preclinical Study Evaluates Cannflavins A and B in Glioblastoma Cell Models

Preclinical Study Evaluates Cannflavins A and B in Glioblastoma Cell Models

Preclinical Study Evaluates Cannflavins A and B in Glioblastoma Cell Models

Mar 2

Canurta Therapeutics Partners with extractX to Integrate Proprietary Extraction Expertise into Enhanced Mobile Lab Platform

Canurta Therapeutics Partners with extractX to Integrate Proprietary Extraction Expertise into Enhanced Mobile Lab Platform

Canurta Therapeutics Partners with extractX to Integrate Proprietary Extraction Expertise into Enhanced Mobile Lab Platform

Feb 17

Canurta Inc. Announces Strategic MOU with International Business University and IPTP to Advance Community-Led Energy and Digital Infrastructure Across the Americas

Canurta Inc. Announces Strategic MOU with International Business University and IPTP to Advance Community-Led Energy and Digital Infrastructure Across the Americas

Canurta Inc. Announces Strategic MOU with International Business University and IPTP to Advance Community-Led Energy and Digital Infrastructure Across the Americas

Feb 5

Canurta Completes First Tranche with PHRX, Expands U.S. Operations, and Advances Biosynthesis Scale-Up

Canurta Completes First Tranche with PHRX, Expands U.S. Operations, and Advances Biosynthesis Scale-Up

Canurta Completes First Tranche with PHRX, Expands U.S. Operations, and Advances Biosynthesis Scale-Up

Feb 3

Canurta Naturals to Lead Operational Transition at FSOil Facility, Expanding cGMP Botanical Extraction Capacity in North America

Canurta Naturals to Lead Operational Transition at FSOil Facility, Expanding cGMP Botanical Extraction Capacity in North America

Canurta Naturals to Lead Operational Transition at FSOil Facility, Expanding cGMP Botanical Extraction Capacity in North America

Jan 27

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

Cannflavin B as a Potential Therapeutic Modulating Behavioral and Neuronal Systems Alterations in a Valproic Acid Model

Jan 14

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Canurta Announces Completion of First Tranche in Strategic Transaction with PharmaDrug Inc.

Jan 6

Unlocking the Therapeutic Potential of Nature’s Rarest Small Molecules

Unlocking the Therapeutic Potential of Nature’s Rarest Small Molecules

Unlocking the Therapeutic Potential of Nature’s Rarest Small Molecules

Dec 30, 2025

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Strategic Mergers and Upcoming CNR-401 Research Showcase at ALS/MND Symposium

Nov 28, 2025

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Canurta Therapeutics Enters Definitive Agreement with PharmaDrug Inc. to Accelerate Strategic Growth and Public Market Access

Oct 31, 2025

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Canurta Finalizes PHRX Agreement, Publishes ALS and Antifungal Research, and Expands Global IP Portfolio

Oct 31, 2025

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Canurta Launches Satoshi Trials, Advances CNR-401, and Expands Public Market Strategy

Oct 8, 2025

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Canurta Signs PHRX LOI, Expands Pipeline, and Advances AI Platform Development

Aug 1, 2025

Transforming Rare Polyphenols into Botanical Drugs

Stay connected & receive updates on new discoveries, product innovation and more.

Yes, I consent to receiving emails from Canurta Therapeutics about news, updates, and relevant content. I understand I can unsubscribe at any time.

Thank you for subscribing.

© 2025 Canurta, Inc. All rights reserved.

bottom of page